Jas-alias schreef op 19 december 2018 13:33:
Dit is nieuw toch?
Galapagos NV initiated with an Overweight at Cantor FitzgeraldCantor Fitzgerald analyst Eliana Merle started Galapagos NV with an Overweight rating and $130 price target. 2019 will be the year that filgotinib could differentiate itself among the JAK inhibitors, Merle tells investors in a research note. The analyst thinks filgotinib's potential is underappreciated and that upside could come from Phase 3 readouts that will show its profile.
Gilead, Galapagos NV analyst commentary at Cantor Fitzgerald Gilead price target raised to $92 from $88 at Cantor Fitzgerald. Cantor Fitzgerald analyst Alethia Young raised her price target for Gilead Sciences (GILD) to $92 after her firm increased its peak 2027 filgotinib sales estimate from $2.75B to $4.0B. Gilead books revenues in the U.S. and ~20% of sales are outside the U.S., so filgotinib is a key pipeline product not only for Galapagos NV (GLPG), but also for Gilead, Young tells investors in a research note. She reiterates an Overweight rating on the shares.